CTMX: CytomX Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $462K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2025-11-06 | Mccarthy Sean A. | CEO | $462K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Fell below 5% | Point72 Asset Management, L.P. | 3.60% | SEC | |
| 2026-08-14 | 13G amendment | Kynam Capital Management, LP | 9.96% | SEC | |
| 2026-08-07 | New 13G stake | STATE STREET CORPORATION | 5.40% | SEC | |
| 2026-08-03 | New 13G stake | BANK OF AMERICA CORP /DE/ | 7.00% | SEC | |
| 2026-07-27 | New 13G stake | BlackRock, Inc. | 7.60% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.